Alessandri M, Fusco B M, Maggi C A, Fanciullacci M
Institute of Internal Medicine and Therapeutics IV, University of Florence, Italy.
Life Sci. 1991;48(24):2301-8. doi: 10.1016/0024-3205(91)90266-e.
The ocular effects of substance P (SP) were studied in 13 normal volunteers. Various concentrations of SP (0.135, 1.35 and 135 micrograms per 100 microliters) were instilled into the conjunctival sac and pupillary area changes were evaluated by means of an electronic pupillometer. The ability of SP to modify the mydriasis induced by pretreatment with 1% homatropine eyedrops was also studied. The instillation of SP produced miosis in a dose-dependent manner without provoking any ocular disturbances. Furthermore, the highest concentration tested was unable to reduce the homatropine-induced mydriasis. These findings indicate that SP exerts a pupillokinetic action in humans which probably occurs via a receptor mechanism. Since muscarinic blockade is not overcome by the peptide instillation, the results do not clarify whether SP causes miosis acting on iris muscles and/or cholinergic fibres.
在13名正常志愿者中研究了P物质（SP）的眼部效应。将不同浓度的SP（每100微升0.135、1.35和135微克）滴入结膜囊，并通过电子瞳孔计评估瞳孔区域的变化。还研究了SP改变1%后马托品滴眼液预处理引起的散瞳作用的能力。SP的滴入以剂量依赖的方式产生缩瞳，且未引发任何眼部干扰。此外，所测试的最高浓度无法降低后马托品引起的散瞳。这些发现表明，SP在人类中发挥瞳孔运动作用，这可能是通过受体机制发生的。由于肽的滴入并未克服毒蕈碱阻断作用，因此结果并未阐明SP是作用于虹膜肌肉和/或胆碱能纤维而导致缩瞳。
